Collegium Announces the Closing of $980 Million Syndicated Credit Facility

Core Viewpoint - Collegium Pharmaceutical, Inc. has successfully closed its inaugural syndicated credit facility of $980 million, which will enhance its financial flexibility and support future business development opportunities [1][2]. Group 1: Credit Facility Details - The credit facility consists of a $580 million initial Term Loan, a $300 million Delayed Draw Term Loan, and a $100 million revolving credit facility, maturing in 2030 [1]. - The initial Term Loan was utilized to repay approximately $581 million of the previous $646 million term loan [1]. - The interest rate for the loans under the Credit Facility is based on the Secured Overnight Financing Rate (SOFR) plus a spread of 2.75% to 3.75%, with the closing rate set at SOFR plus 2.75% [2]. Group 2: Financial Outlook and Strategy - The new credit facility is expected to result in significant annualized interest savings, improving the company's debt terms [2]. - The additional capital will provide the company with the flexibility to pursue long-term value through the expansion and diversification of its product portfolio [2]. - Collegium is focused on growing its commercial portfolio, particularly through its leading product Jornay PM, which is aimed at ADHD treatment [3].